Notice of AGM

RNS Number : 8380F
AstraZeneca PLC
12 March 2020
 

12 March 2020 11:00 GMT

 

Notice of Annual General Meeting

 

AstraZeneca PLC (the Company) announced today the publication of its Notice of Annual General Meeting 2020 and Shareholders' Circular (the Notice).

 

The Notice has been submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/nsm. The Notice is also available on the Company's website at  www.astrazeneca.com/agm .

 

The Company's Annual Report and Form 20-F Information 2019 was published on 3 March 2020.

 

The Notice is being despatched to shareholders today.

 

The meeting place for the Annual General Meeting (AGM) will be Leonardo Royal Hotel London Tower Bridge, 45 Prescot St, London, E1 8GP and the AGM will commence at 2.30 pm (BST) on 29 April 2020.

 

The Company continues to monitor the situation in relation to COVID-19 and will notify shareholders via our website, www.astrazeneca.com as soon as practicably possible if there are any changes to the AGM arrangements.  Shareholders are reminded of their right to appoint the Chairman of the AGM, or any other person, as their proxy to attend the meeting and vote on their behalf.

 

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @ AstraZeneca .

Media Relations



Gonzalo Viña


+44 203 749 5916

Rob Skelding

Oncology

+44 203 749 5821

Rebecca Einhorn

Oncology

+1 301 518 4122

Matt Kent

BioPharmaceuticals

+44 203 749 5906

Angela Fiorin

BioPharmaceuticals

+44 1223 344 690

Jennifer Hursit

Other

+44 203 749 5762

Christina Malmberg Hägerstrand

Sweden

+46 8 552 53 106

Michele Meixell

US

+1 302 885 2677

Investor Relations



Thomas Kudsk Larsen


+44 203 749 5712

Henry Wheeler

Oncology

+44 203 749 5797

Christer Gruvris

BioPharmaceuticals

(Cardiovascular, Metabolism)

+44 203 749 5711

Nick Stone

BioPharmaceuticals (Renal) Environmental, Social and Governance

+44 203 749 5716

Josie Afolabi

BioPharmaceuticals (Respiratory)

 

+44 203 749 5631

Tom Waldron

Other medicines

+44 7385 033 717

Craig Marks

Finance

Fixed income

+44 7881 615 764

Jennifer Kretzmann

Corporate access

Retail investors

+44 203 749 5824

US toll-free


+1 866 381 72 77


Adrian Kemp
Company Secretary
AstraZeneca PLC

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NOAGPUPGWUPUGMG

Companies

AstraZeneca (AZN)
UK 100

Latest directors dealings